Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
May 10, 2017 21:32 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate...
Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 08, 2017 16:08 ET
|
Dermira, Inc.
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a...
Dermira to Present at Needham 16th Annual Healthcare Conference
March 28, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
March 21, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will...
Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
March 21, 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
March 17, 2017 08:30 ET
|
Dermira, Inc.
New data for the Axillary Sweating Daily Diary patient-reported outcome instrument from the glycopyrronium tosylate Phase 2 trial in primary axillary hyperhidrosis to be highlighted Additional data...
Galectin Therapeutics to Present at 29th Annual ROTH Conference
March 09, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 07, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
March 06, 2017 08:30 ET
|
Galectin Therapeutics
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) --...